Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to food intake, stimulating insulin production and suppressing glucagon secretion. GLP-1 agents demonstr